Chemotherapy and other traditional cancer therapies do a great job of shrinking most tumors. But some cancer cells manage to escape and seed new tumor growth — a problem that has vexed scientists for years.
Now a Cambridge start-up is going to test a drug it hopes will target those cancer cells that survive the first salvo. The firm, Verastem Inc., has just begun recruiting patients with ovarian cancer for a clinical trial in which it will test its drug, along with chemotherapy, to see if the combination produces a more complete and effective treatment.
Comments
The photo doesn't credit the people in it...